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Volume 6Available online xxxBackground: Checkpoint inhibitors in melanoma can lead to self-immune side-effects such as vitiligo-like
depigmentation (VLD). Beyond the reported association with favorable prognosis, there are limited data regarding
VLD patient features and their echo on the therapeutic outcomes.
Methods: To assess the association between VLD and a series of clinical and biological features as well as therapeutic
outcomes, we built an observational cohort study by recruiting patients who developed VLD during checkpoint inhibitors.
Results: A total of 148 patients from 15 centers (101 men, median age 66 years, BRAF mutated 23%, M1c 42%, Eastern
Cooperative Oncology Group (ECOG) status 0/1 99%, normal lactate dehydrogenase 74%) were enrolled. VLD was
induced by ipilimumab, programmed cell death-1 (PD-1) inhibitors, and their combination in 32%, 56%, and 12%,
respectively. The median onset was 26 weeks and it was associated with other skin and nonskin toxicities in 27%
and 28%, respectively. After 3 years of VLD onset, 52% (95% confidence interval 39% to 63%) were progression free
and 82% (95% confidence interval 70% to 89%) were still alive. The overall response rate was 73% with 26%
complete response. Univariable analysis indicated that BRAF V600 mutation was associated with a better overall
survival (P ¼ 0.028), while in multivariable analysis a longer progression-free survival was associated with BRAF
V600 (P ¼ 0.093), female sex (P ¼ 0.008), and M stage other than 1a (P ¼ 0.024). When VLD occurred, there was a
significant decrease of white blood cell (WBC) count (P ¼ 0.05) and derived WBC-to-lymphocytes ratio (dWLR; P ¼
0.003). A lower monocyte count (P ¼ 0.02) and dWLR (P ¼ 0.01) were also reported in responder patients.
Conclusions: Among VLD population, some features might help to identify patients with an effective response to
immunotherapy, allowing clinicians to make more appropriate choices in terms of therapeutic options and duration.
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- Issue 2 - 2021(MM) in 2011, this new class of drugs, comprising both
cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) and
programmed cell death-1 (PD-1)/PD-1 ligand-1 (PD-L1) in-
hibitors, utilized alone or in combination, has profoundly
changed oncology practice.1 This Copernican revolution has
not proved to be without challenges. While the ability to
achieve long-lasting response in a subset of patients is a
well-known effect of checkpoint inhibitors, no well-defined
consensus has been made for duration of therapy, predic-
tive biomarkers, response criteria, and significance ofhttps://doi.org/10.1016/j.esmoop.2021.100064 1
ESMO Open M. Guida et al.toxicity. The latest challenge is a complex paradigm change
enforced by this therapeutic course: by removing key im-
mune inhibitors (CTLA-4 and PD-1) to restore active T-cell
response against tumor cells, these agents could also break
out a new class of side-effects as a result of overstimulation
of the immune system, known as immune-related adverse
events (irAEs).2-4 Among the irAEs, skin reactions, colitis,
pneumonitis, and endocrinopathies occur more
commonly.1-3
Although the knowledge of the self-immune nature of
this toxicity led to the development of a standardized
management protocol,4 unresolved issues remain to be
clarified, particularly, regarding the various types of side-
effects and their correlation to clinical outcomes. It is
likely that irAEs could be related to the disease and the
checkpoint inhibitor used.5 The most striking case in this
scenario is the vitiligo-like depigmentation (VLD) induced by
checkpoint inhibitors in MM patients. This skin toxicity
mirrors CD (cluster of differentiation) 8þ reactivity against
antigens coexpressed in melanoma cells and normal mela-
nocytes, evident from the examination of clonotypically
identical cytotoxic T cells infiltrating the tumor lesions and
skin depigmented areas.6 Some studies support that VLD
induced by any kind of therapy is a prognostic factor
associated with a better overall survival (OS) in patients
with stage III and IV melanoma.7-10 Data from a systematic
review and meta-analysis reported an incidence of this skin
toxicity in only 3.4% of melanoma patients treated with
immunotherapy.11 More recent data indicate a higher inci-
dence of approximately 10%-28% among patients treated
with checkpoint inhibitors.12-18 However, owing to the
limited number of patients included in these reports, no
definitive evidence could be gathered about the significance
of VLD arising from the use of checkpoint inhibitors as well
as the clinical and biological features associated with VLD.
Here, we report a multi-institutional study within the
Italian Melanoma Intergroup (IMI) centers, comprising a
large population of 148 MM patients who developed VLD
during treatment with CTLA-4 and PD-1 inhibitors as a
single agent or in combination.We outline the profile of the
patients with VLD and define their therapeutic outcomes.
Moreover, we performed univariable and multivariable an-
alyses to assess the association between therapy outcomes
and a series of clinical and biological features as well as the
trend of some peripheral blood parameters.
PATIENTS AND METHODS
Patients, treatment, and assessment
We built an observational cohort study by retrospectively
recruiting patients with stage IV melanoma from 15 IMI
centers. Patients were considered eligible if they developed
VLD during treatment with ipilimumab, or PD-1 inhibitors
(pembrolizumab or nivolumab), or the combination of ipi-
limumab and nivolumab. Patients were treated according to
the standard dose and schedule of checkpoint inhibitors. All
patients were routinely screened for VLD by a dermato-
logical examination performed once a month during2 https://doi.org/10.1016/j.esmoop.2021.100064treatment. VLD was defined as the appearance of hypo-
pigmented skin areas and was classified as localized or
generalized according to the distribution of the lesions.
Generalized vitiligo was defined as a bilateral symmetrical
form, including acrofacial vitiligo, diffuse vitiligo vulgaris,
and universal vitiligo. Localized vitiligo was defined as a
unilateral asymmetrical form, including focal types,
segmental types, halo nevi, and perimetastatic types. The
mixed types of vitiligo were defined as a mixed distribution
pattern of both generalized and localized vitiligo.10-19
Patients were eligible if they underwent at least a
radiological assessment by RECIST (version 1.1).20 The
radiological assessment was performed in all the centers as
per clinical practice every 3/4 months. For all patients, we
systematically collected the clinical data such as primary
melanoma histology report, anatomic site, TNM stage,
timing of main disease events, metastatic sites, treatments,
response to therapy, Eastern Cooperative Oncology Group
(ECOG), kind and timing of vitiligo onset, lactate dehydro-
genase (LDH) value, and white blood cell (WBC) counts
before and during immunotherapy. The study was approved
by the local Ethics Committee of Istituto Tumori ‘Giovanni
Paolo II’ of Bari (protocol 633/Ethics Committee of 27 June
2017).Statistical analysis
OS and progression-free survival (PFS) were calculated from
vitiligo onset and were estimated with the KaplaneMeier
method. The choice of using VLD diagnosis rather than
immunotherapy initiation as the starting point is motivated
by the attempt to avoid overestimation of survival time
because of the so-called immortal time bias, occurring
when time not at risk is erroneously included in the anal-
ysis. In our cohort, only patients developing VLD are
included in the analysis. Therefore patients, by design, are
not at risk of death from the start of the treatment, but
from the moment they are diagnosed with VLD. Indeed, the
design is based on a biological rationale that the onset of
VLD in itself triggers an antitumor response in synergy with
checkpoint blockade. For completeness, alternative ana-
lyses starting from immunotherapy initiation are shown in
Supplementary Material, available at https://doi.org/10.
1016/j.esmoop.2021.100064. Survival differences among
groups of patients were tested through the log-rank test. To
investigate the relationship between covariates and events
(death or progression of disease), we fitted both univariable
and multivariable Cox proportional hazard models. Consid-
ering the small number of events, we built parsimonious
models to avoid overfitting. Predictors for the PFS model
(48 observed events) were chosen a priori, based on subject
matter knowledge, and included stage of metastatic disease
(M1a versus M1b, M1c, M1d), BRAF mutation (presence
versus absence), the line of therapy (first line versus further
line), LDH (above versus below upper limit of normal), type
of vitiligo (I versus II and III), sex, and age. In the OS model
(18 observed events), we had to perform a stricter selec-
tion, and only stage, line of therapy, LDH, and age wereVolume 6 - Issue 2 - 2021
Table 1. Clinical and disease features of patients developing vitiligo-like
depigmentation during therapy with checkpoint inhibitors




Age at MM diagnosis, median (25th-75th percentiles) 61 (48-70)
Checkpoint inhibitor, n (%)
Ipilimumab 47 (32)
PD-1 inhibitor 83 (56)
Ipilimumab plus PD-1 18 (12)
Line of therapy during which vitiligo appeared, n (%)
First line 77 (52)
Second line 43 (29)
Third line 22 (15)
Fourth line 6 (4)
Type of melanoma, n (%)
Cutaneous 124 (84)
Mucosal 6 (4)
Unknown origin 18 (12)
Anatomic site of primary melanoma, n (%)
Head and neck 18 (12)
Trunk 51 (34)
Upper limbs 6 (4)
Lower limbs 49 (33)
Mutation status, n (%)
BRAF 34 (23)
Wild type 114 (77)




Previous adjuvant therapy, n (%)
Yes 24 (16)
No 124 (84)













ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; MM,
metastatic melanoma; NA, not assessed; PD-1, programmed cell death-1; ULN,
upper limits of normal.
a At therapy-induced vitiligo.
M. Guida et al. ESMO Openincluded. Absolute values of lymphocytes, WBCs, and
monocytes have been compared at two different time
points (at the beginning of therapy causing vitiligo and at
vitiligo onset) through paired-sample Wilcoxon test because
ShapiroeWilk normality test indicated that data did not
follow the normal distribution. Moreover, we computed a
derived WBC-to-lymphocyte ratio (dWLR) with the
following formula: dWLR ¼ (WBC  Lymphocytes)/Lym-
phocytes. Ratio values have also been tested with paired
sample Wilcoxon test. All analyses were performed with R
version 3.6.2 (R Foundation for Statistical Computing,
Vienna, Austria). ‘statix’ ‘ggpubr’, and ‘tidyverse’ R packages
have been used. Finally, to test differences in monocytes,
lymphocytes, WBC, and dWLR values in terms of type of
response (partial and complete response versus absence ofVolume 6 - Issue 2 - 2021radiologic objective response) and the two timepoints,
analysis of variance of aligned rank-transformed data, a
nonparametric test, was performed, because the normality
assumption was not reached, which did not allow the use of
two-way analysis of variance. ‘ARTtool’ R package was used.
RESULTS
Vitiligo features
In the time span from June 2007 to November 2017, 148
[101 (68%) male and 47 (32%) female] stage IV melanoma
patients treated with checkpoint inhibitors developed VLD.
The vitiligo-inducing therapy included ipilimumab in 47
(32%) patients, PD-1 inhibitors in 83 (56%) patients, and a
combination therapy of ipilimumab and nivolumab in the
remaining 18 (12%) patients. The main clinical features of
this population and of VLD are summarized in Table 1 and
Supplementary Material, available at https://doi.org/10.
1016/j.esmoop.2021.100064.Clinical outcomes
With a median follow up of 46 months, progression was
observed in 48 patients, 18 of whom died. Median PFS time
was 42 months, with 52% [95% confidence interval (CI) 39%
to 63%] of the cohort patients still alive and progression
free 3 years after VLD onset (Figure 1A). The 25th percentile
of OS time was 42 months, with 82% (95% CI 70% to 89%)
of the cohort patients still alive 3 years after VLD onset
(Figure 1B).
Regarding the response, we found a global overall
response rate of 73% (108), with 26% (38) of complete
response. Moreover, stable disease was reported in 20%
(n ¼ 30) of patients, and only 7% (n ¼ 10) experienced a
progressive disease as best response. The rates of overall
response and complete response among the different
treatments were 64% (n ¼ 30) and 32% (n ¼ 15) for ipili-
mumab, 78% (n ¼ 65) and 19% (n ¼ 16) for PD-1 inhibitors,
and 72% (n ¼ 13) and 39% (n ¼ 7) for the combination
therapy, respectively. Likely due to this similar response
rate, there were no statistically significant differences in OS
and PFS among the different checkpoint inhibitors.
However, among VLD patients, a longer PFS was found in
the Cox multivariable regression analysis in women with
respect to men (hazard ratio 0.34, 95% CI 0.16-0.76, P ¼
0.008) and for M stage other than M1a (hazard ratio 0.45,
95% CI 0.22-0.90, P ¼ 0.024). Moreover, the presence of
BRAF V600 mutation was associated with a better OS, with
no deaths occurring in the mutation carrier (P ¼ 0.028;
Figure 1C). The Cox univariable and multivariable analyses
results are summarized in Tables 2 and 3.WBC trend and VLD
The values of WBC, lymphocytes, monocytes, and dWLR at
beginning of treatment and onset of VLD were available for
88 patients (60%). When vitiligo occurred, we found a sig-
nificant lowering of WBC count (P ¼ 0.05) and dWLR (P ¼
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Figure 1. KaplaneMeier curves of (A) progression-free survival and (B) overall survival (OS) in the entire population of 148 patients developing vitiligo-like
depigmentation (VLD) during treatment with checkpoint inhibitors. (C) OS by BRAF status (P [ 0.028).
ESMO Open M. Guida et al.available at https://doi.org/10.1016/j.esmoop.2021.100064).
Then, we test the variability of absolute values of these
hematological parameters across VLD patient groups with
and without RECIST response. We found that in responder
patients there was a significant lowering of monocyte count
and dWLR (F1,173 ¼ 5.34, P ¼ 0.02, F1,173 ¼ 6.03, P ¼ 0.01,
respectively; Figure 2B).DISCUSSION
In melanoma patients, VLD is a dermatological, sponta-
neous, or treatment-induced phenomenon characterized by
a loss of epidermis melanocytes due to antitumor immunity,
with the pathogenesis likely based on both antibody and
CD8þ activation against antigens shared by melanoma and
melanocytes.21 Thus, it is expected that this kind of vitiligo,
as a surrogate of robust antimelanoma immunity, could be
associated with improved survival. At present, beyond case
reports and small single-center experiences, there are
limited data regarding the feature profile of patients with
this irAE and its influence on the therapeutic outcomes with
these drugs. To clarify this, we performed the largest
observational cohort study of 148 patients with VLD
induced by CTLA-4 and PD-1 inhibitors.4 https://doi.org/10.1016/j.esmoop.2021.100064A previous meta-analysis by Teulings et al.11 focused on
the incidence of VLD in a large population of stage III and IV
melanoma patients from 139 studies of immunotherapy
including 28 studies with CTLA-4 and PD-1 blockade. The
pooled cumulative incidence of VLD was 3.4% (total pa-
tients: 304) with 2% due to checkpoint inhibitors (74 pa-
tients). However, this review reported PFS and OS data from
only 35 and 18 patients, respectively. Although a significant
survival benefit was shown with a doubling of PFS and a
quadruplication of OS in patients who developed VLD
compared with those who did not, the analysis accounted
for only four patients treated with checkpoint inhibitor.
In our analysis, we reported 36-month PFS and OS rates
of 52% and 82%, which were much longer than those
previously reported.22-24 Likewise, VLD was also associated
with a remarkable response rate of 73% with 26% of
complete response, which is much higher than those re-
ported in registrative trials.22-24 Thus, we found no proper
comparison with unselected melanoma population in a real-
word setting due to the late occurrence of VLD (median
onset about 6 months) and the consequent selection of a
long-lasting responder population. Of note, similar results
were reported in five small retrospective analyses by Quach
et al.,12 Nakamura et al.,16 Freeman-Keller et al.,17Volume 6 - Issue 2 - 2021
Table 2. Univariable and multivariable Cox regression analyses of PFS in
melanoma patients treated with checkpoint inhibitors and who devel-
oped VLD




Female 0.42 (0.21-0.85) 0.016
BRAF status
Wild-type 1
Mutation carrier 0.45 (0.19-1.05) 0.065
Site of primary tumor
Trunk 1 0.536
Upper limb 0.98 (0.13-7.47)
Lower limb 1.05 (0.54-2.06)
Unknown origin 0.36 (0.11-1.25)
Mucosal 1.22 (0.28-5.31)
Head 1.41 (0.60-3.30)
Age at MM diagnosis 1.02 (1.00-1.04) 0.114
Line of therapy
First 1
Second or further 0.57 (0.32-1.02) 0.060





M Stage at treatment (binary)
M1a 1
M1b, M1c, M1d 0.83 (0.47-1.48) 0.527
LDH (binary)
<ULN 1





Type of VLD (binary)
I 1 0.400




Female 0.34 ( 0.16-0.76)
BRAF status
Wild type 1 0.093
Mutation carrier 0.46 (0.19-1.14)
Age at MM diagnosis 1.01 (0.98-1.03) 0.574
Line of therapy
First 1 0.206
Second or further 0.67 (0.36-1.24)
M stage (binary)
M1a 1 0.024




Type of VLD (binary)
I 1 0.664
II, III 1.15 (0.62-2.11)
Bold entries are statistically significance findings.
CI, confidence interval; HR, hazards ratio; LDH, lactate dehydrogenase; MM, meta-
static melanoma; PFS, progression-free survival; ULN, upper limits of normal; VLD,
vitiligo-like depigmentation.
Table 3. Univariable and multivariable Cox regression analyses of OS in
melanoma patients treated with checkpoint inhibitors and who devel-
oped vitiligo-like depigmentation












Age at MM diagnosis 1.02 (0.99-1.06) 0.203
Line of therapy
First 1








Others 0.56 (0.22-1.42) 0.222
LDH (binary)
<ULN 1







II, III 1.16 (0.44-3.04) 0.757
OS multivariate analysis
Age at MM diagnosis 1.02 (0.98-1.05) 0.364
Line of therapy
First 1






>ULN 1.92 (0.65-5.69) 0.242
CI, confidence interval; HR, hazards ratio; LDH, lactate dehydrogenase; MM, meta-
static melanoma; NE, not estimable; OS, overall survival; ULN, upper limits of
normal.
M. Guida et al. ESMO OpenBottlaender et al.,25 and Nakano et al.26 and in one pro-
spective study by Hua et al.14 However, a limited number of
patients were included in these reports (N ¼ 10, 19, 9, 16,
30, and 17, respectively). Because of these small sample
sizes, some data are conflicting and no correlation wasVolume 6 - Issue 2 - 2021found with other clinical or biological characteristics.
Nakamura et al.16 reported a response rate of only 41% in
VLD patients, which was the same as that of patients
without VLD, and Hua et al.14 did not find a statistically
significant advantage in OS between the two groups after
correction for time load bias. Similar data were reported in
a larger retrospective study of the French pharmacovigi-
lance database that described the outcomes of 94 mela-
noma patients with VLD associated with checkpoint
inhibitors.27 Although the response rate and the detailed
features of the patient population were not reported, a
median PFS of 22 and 20 months for pembrolizumab and
nivolumab, respectively, and an OS rate of 65% in the entire
population at 33 months of median follow-up were
documented.27https://doi.org/10.1016/j.esmoop.2021.100064 5
A
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Figure 2. (A) Boxplots showing a significant variation of absolute value of white blood cells (WBCs) and WBC to lymphocytes ratio between the beginning of
immunotherapy and the vitiligo-like depigmentation onset. (B) At those time-points, a lower monocyte count (P [ 0.02) and dWLR were reported in responder
versus nonresponder patients.
ESMO Open M. Guida et al.In our population, the main features of VLD were similar
to those previously reported. The skin depigmentation
onset occurred on photoexposed areas and was not asso-
ciated with the Koebner phenomenon, which normally
characterizes common vitiligo, as reported in eight patients
of the prospective study by Larsabal et al.13 In our6 https://doi.org/10.1016/j.esmoop.2021.100064population, the onset of VLD was earlier in the combination
therapy than in single checkpoint inhibitor, which was
consistent with previously reported data of phase III trial
CheckMate 06722 as well as a single-center retrospective
analysis.18,26,27 Interestingly, we showed that after VLD
onset, there was no statistical difference in clinicalVolume 6 - Issue 2 - 2021
M. Guida et al. ESMO Openoutcomes regardless of whether the checkpoint was utilized
as a single agent or in combination. This could be proof of
the independent strength of the antimelanoma immunity
accompanying this skin manifestation. A further hint in
favor of the positive intrinsic and independent prognostic
values of VLD could be deduced by the fact that in both
univariable and multivariable survival analyses of this pop-
ulation, there were very few other clinical and biological
characteristics that were able to positively influence clinical
outcomes. Ultimately, it is conceivable that incidence of
VLD identifies a homogeneous population of patients
already with a favorable prognosis, which is further
emphasized by the immunological therapy. This hypothesis
could explain the unexpected data of a longer PFS in M
stage other than M1a. Intriguingly, we found a positive
correlation with a probability of a longer PFS in female
patients, which is in contrast to a recent meta-analysis that
revealed that the magnitude of benefit to checkpoint in-
hibitors is sex dependent with a significant advantage for
male patients.28 However, this sex difference arises from a
heterogeneous spectrum of studies on different type of
cancers.
Another compelling result is the evidence of better sur-
vival in the presence of the BRAF V600 mutation (Figure 2).
Better clinical outcomes in BRAF-mutated patients
compared with the wild type were previously reported in
CheckMate 067 for all kinds of immunotherapy.22 More-
over, a genetic signature eliciting a deeper immunogenicity
has long been described in BRAF-mutated melanoma.29 Of
interest, 60% of our patients with BRAF mutation had been
pre-treated with BRAF/MEK inhibitor drugs. As already
known, this treatment could induce an antigen and
immunological modulation, which could reactivate the
melanoma immune response,30,31 thereby making these
patients more responsive to immunotherapy with check-
point inhibitors.
Finally, among the blood profile, we found a lowering of
WBC and dWLR when VLD occurs compared with the
beginning of immunotherapy. Even if we looked at late
variation, as the median time of vitiligo onset is about 6
months from the beginning of immunotherapy, these find-
ings could be a confirmation of previous several reports that
documented earlier differences in lymphocyte, neutrophils-
to-lymphocytes ratio, or monocyte as predictive bio-
markers.32-35 We chose to investigate the ratio (dWLR) that
accounts for the sum of neutrophils and monocytes in the
numerator as these cells are well-known markers of in-
flammatory effector functions and regulatory properties
essential for malignancy growth and immune escape.32,36-38
We also found a decrease of this ratio as well as of
monocyte count at VLD onset in patients with partial or
complete response compared with nonresponder patients.
Such findings might mirror a major recruitment of immu-
nosuppressive cellular actors in the tumor microenviron-
ment of nonresponder patients for which the main source is
circulating monocytes. The negative prognostic significance
of monocytes and monocytic myeloid-derived suppressor
cells has been reported in patients with diffuse large B-cellVolume 6 - Issue 2 - 2021lymphoma under R-CHOP therapy,39 whereas no data are
available in solid tumors.
Despite these interesting findings, some limitations of
this analysis deserve to be underlined. First, it is a retro-
spective study with a long duration of recruitment. In
addition, the small number of deaths during follow-up re-
strains the conclusions along with the need for any asso-
ciations to be confirmed in prospective studies due to the
large number of statistical analysis drawn. Unlike other
similar studies12-17 we did not match our population with a
comparison one without VLD. This matching was made
difficult by the long period of the accrual and heterogeneity
of our VLD population (treated with different checkpoint
inhibitors and lines of therapy) as well as due to the
enrichment of responder patients. Moreover, our mainly
goal is to define the clinical and biological features associ-
ated with better outcomes among patients with checkpoint
blockade-induced VLD. Thus these areas could be a starting
point to validate the detailed molecular and immunological
apparatus that supports VLD and orchestrates the effective
antitumor reaction. Finally, the identification of antigen-
specific immune effector cells which mediated VLD could
be the next step to assess and monitor the clinical benefit
associated with this irAE.
CONCLUSIONS
Our data clearly show that patients who develop VLD during
treatment with checkpoint inhibitors have a longer survival
and a higher response rate with respect to those reported
in all large controlled clinical studies. In our opinion, it is
likely that these beneficial outcomes are due to the selec-
tion of a population with an intrinsic capability to imple-
ment a powerful antitumor response emphasized by the
treatment with checkpoint inhibitors.
Although VLD cannot be used as a predictor of response,
as it follows and does not anticipate a response, our data
could contribute to better recognition of patients with an
effective antimelanoma immunity and may help clinicians in
decision making regarding therapeutic options and dura-
tion. This could be particularly useful in case of PD-1
blockade wherein the treatment interruption after a com-
plete response remains an unresolved question.
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